AbbVie (NYSE: ABBV), today announced that nine (9) provinces have provided accelerated public coverage of EPKINLY™. EPKINLY is a treatment for adult patients with Relapsed or Refractory diffuse large ...

Strengthens Lyell’s clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidateData from ImmPACT’s ...

Stanford Medicine researchers discovered a method to induce cancer cell death by manipulating proteins involved in apoptosis.

Lymphoma, a cancer of the immune system, is silently ravaging the health of Black men across America. This insidious disease, ...

AbbVie (NYSE: ABBV) today announced that nine provinces have provided accelerated public coverage of EPKINLY™. EPKINLY is a treatment for adult patients with Relapsed or Refractory diffuse large ...

Ladenburg analyst Aydin Huseynov raised the firm’s price target on Marker Therapeutics (MRKR) to $19 from $11 and keeps a Buy rating on the shares. Ladenburg is becoming more confident in seeing ...

Monday announced that nine provinces have approved accelerated public coverage of Epkinly, a treatment for adult ...

Yescarta (axicabtagene ciloleucel) has been approved as a treatment for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma ...

DLBCL = Diffuse large B-cell lymphoma; EORTC = European Organisation for the Research and Treatment of Cancer; FDG = 2-18F-fluoro-2-deoxyglucose; GELA = Groupe d'Etudes des Lymphomes de l'Adulte ...

Harvard Medical School unveils an AI digital pathology tool that outperforms state-of-the-art deep learning methods, ...